Patents by Inventor Daniele Biasci
Daniele Biasci has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12285484Abstract: The disclosure herein relates to novel cancer-associated antibodies that are used in the treatment and diagnosis of a cancer. The complete polypeptide and nucleic acid consensus sequences of the antibodies disclosed herein are reconstructed in silico.Type: GrantFiled: September 19, 2019Date of Patent: April 29, 2025Assignee: ABSCI CORPORATIONInventors: Daniele Biasci, Ines De Santiago Domingos De Jesus, Berke Cagkan Toptas
-
Publication number: 20250109209Abstract: The disclosure herein relates to the development and production of novel antibodies and antigen binding fragments thereof that bind TL1A and that are useful in the treatment, prevention and diagnosis of a disease, disorder or inflammation including, for example, autoimmune diseases including rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, systemic lupus erythematosus, asthma, ulcerative colitis, Crohn's disease, psoriasis, primary biliary cirrhosis, primary biliary cholangitis, ankylosing spondylitis, and fibrosis including intestinal fibrosis, pulmonary fibrosis, and liver fibrosis. Some of the elements of final antibody structure being designed de novo by a computer system and its data training set without reference to a specific reference molecule.Type: ApplicationFiled: October 2, 2024Publication date: April 3, 2025Inventors: Daniele Biasci, Sharrol Bachas, Amir Shanehsazzadeh, Vincent Blay, Matthew Waugh, Simon Levine-Gottreich, Anand Sastry, Douglas Ganini Da Silva, David Spencer, Emily Gage, Matthew McPartlon
-
Publication number: 20250109210Abstract: The disclosure herein relates to the development and production of novel antibodies and antigen binding fragments thereof that bind TL1A and that are useful in the treatment, prevention and diagnosis of a disease, disorder or inflammation including, for example, autoimmune diseases including rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, systemic lupus erythematosus, asthma, ulcerative colitis, Crohn's disease, psoriasis, primary biliary cirrhosis, primary biliary cholangitis, ankylosing spondylitis, and fibrosis including intestinal fibrosis, pulmonary fibrosis, and liver fibrosis. Some of the elements of final antibody structure being designed de novo by a computer system and its data training set without reference to a specific reference molecule.Type: ApplicationFiled: October 2, 2024Publication date: April 3, 2025Inventors: Daniele Biasci, Sharrol Bachas, Amir Shanehsazzadeh, Vincent Blay, Matthew Waugh, Simon Levine-Gottreich, Anand Sastry, Douglas Ganini Da Silva, Matthew McPartlon, Emily Gage, David Spencer
-
Publication number: 20250104804Abstract: The disclosure herein relates to in silico methods for reconstructing complete polypeptide and nucleic acid consensus sequences for novel biologically active protein dimers, including but not limited to antibodies that are useful for the treatment and diagnosis of a cancer, autoimmune condition, or infectious disease.Type: ApplicationFiled: December 6, 2021Publication date: March 27, 2025Inventors: Daniele Biasci, Ines De Santiago Domingos De Jesus, Berke Cagkan Toptas, Goran Rakocevic
-
Publication number: 20250092155Abstract: The disclosure herein relates to novel cancer-associated antibodies and antigen-binding fragments that are used in the diagnosis of a cancer or a metastasis thereof. The disclosure herein relates to novel cancer-associated antibodies and antigen-binding fragments that are used in the treatment of a cancer or a metastasis thereof. The disclosure herein relates to novel chimeric antigen receptor or a T cell receptor fusion protein that comprise one or more cancer-associated antigen-binding domains that are useful for the treatment of a cancer.Type: ApplicationFiled: September 23, 2024Publication date: March 20, 2025Inventors: Daniele Biasci, Goran Rakocevic, Berke Cagkan Toptas, Ines De Santiago Domingos De Jesus
-
Patent number: 12134655Abstract: The disclosure herein relates to novel cancer-associated antibodies and antigen-binding fragments that are used in the diagnosis of a cancer or a metastasis thereof. The disclosure herein relates to novel cancer-associated antibodies and antigen-binding fragments that are used in the treatment of a cancer or a metastasis thereof. The disclosure herein relates to novel chimeric antigen receptor or a T cell receptor fusion protein that comprise one or more cancer-associated antigen-binding domains that are useful for the treatment of a cancer.Type: GrantFiled: April 29, 2020Date of Patent: November 5, 2024Assignee: ABSCI CORPORATIONInventors: Daniele Biasci, Goran Rakocevic, Berke Cagkan Toptas, Ines De Santiago Domingos De Jesus
-
Publication number: 20230331825Abstract: The disclosure herein relates to novel antibodies and antigen binding fragments that are used in the treatment, prevention and diagnosis of COVID-19, the disease caused by SARS-CoV-2. The complete polypeptide and nucleic acid consensus sequences of the antibodies and antigen binding fragments disclosed herein are reconstructed in silico.Type: ApplicationFiled: August 25, 2021Publication date: October 19, 2023Inventors: Goran Rakocevic, Daniele Biasci
-
Publication number: 20220204643Abstract: The disclosure herein relates to novel cancer-associated antibodies and antigen-binding fragments that are used in the diagnosis of a cancer or a metastasis thereof. The disclosure herein relates to novel cancer-associated antibodies and antigen-binding fragments that are used in the treatment of a cancer or a metastasis thereof. The disclosure herein relates to novel chimeric antigen receptor or a T cell receptor fusion protein that comprise one or more cancer-associated antigen-binding domains that are useful for the treatment of a cancer.Type: ApplicationFiled: April 29, 2020Publication date: June 30, 2022Inventors: Daniele Biasci, Goran Rakocevic, Berke Cagkan Toptas, Ines De Santiago Domingos De Jesus
-
Publication number: 20220031841Abstract: The disclosure herein relates to novel cancer-associated antibodies that are used in the treatment and diagnosis of a cancer. The complete polypeptide and nucleic acid consensus sequences of the antibodies disclosed herein are reconstructed in silico.Type: ApplicationFiled: September 19, 2019Publication date: February 3, 2022Inventors: Daniele BIASCI, Ines de Santiago Domingos de JESUS, Berke Cagkan TOPTAS
-
Patent number: 11041206Abstract: The present invention provides a method of assessing whether an individual is at high risk or low risk of inflammatory bowel disease (IBD) progression by determining the expression level of two or more genes in a whole blood sample. Also provided are methods for treating IBD in an individual who is determined to be at high risk or low risk for IBD progression, and kits for assessing whether an individual is at high risk or low risk for IBD progression. Arrays, and methods of providing arrays, of patient-identified selected gene expression products from a whole blood sample of a patient are also provided.Type: GrantFiled: July 5, 2017Date of Patent: June 22, 2021Assignee: Cambridge Enterprise LimitedInventors: Paul A. Lyons, Kenneth G. C. Smith, Eoin F. McKinney, Daniele Biasci, James Lee
-
Patent number: 10640829Abstract: The present invention provides a method of assessing whether an individual is at high risk or low risk of inflammatory bowel disease (IBD) progression by determining the expression level of two or more genes in a whole blood sample. Also provided are methods for treating IBD in an individual who is determined to be at high risk or low risk for IBD progression, and kits for assessing whether an individual is at high risk or low risk for IBD progression. Arrays, and methods of providing arrays, of patient-identified selected gene expression products from a whole blood sample of a patient are also provided.Type: GrantFiled: October 12, 2018Date of Patent: May 5, 2020Assignee: CAMBRIDGE ENTERPRISE LIMITEDInventors: Paul A. Lyons, Kenneth G. C. Smith, Eoin F. McKinney, Daniele Biasci, James Lee
-
Patent number: 10202651Abstract: The present invention provides a method of assessing whether an individual is at high risk or low risk of inflammatory bowel disease (IBD) progression by determining the expression level of two or more genes in a whole blood sample. Also provided are methods for treating IBD in an individual who is determined to be at high risk or low risk for IBD progression, and kits for assessing whether an individual is at high risk or low risk for IBD progression. Arrays, and methods of providing arrays, of patient-identified selected gene expression products from a whole blood sample of a patient are also provided.Type: GrantFiled: July 17, 2017Date of Patent: February 12, 2019Assignee: Cambridge Enterprise LimitedInventors: Paul A. Lyons, Kenneth G. C. Smith, Eoin F. McKinney, Daniele Biasci, James Lee
-
Publication number: 20190032140Abstract: The present invention provides a method of assessing whether an individual is at high risk or low risk of inflammatory bowel disease (IBD) progression by determining the expression level of two or more genes in a whole blood sample. Also provided are methods for treating IBD in an individual who is determined to be at high risk or low risk for IBD progression, and kits for assessing whether an individual is at high risk or low risk for IBD progression. Arrays, and methods of providing arrays, of patient-identified selected gene expression products from a whole blood sample of a patient are also provided.Type: ApplicationFiled: October 12, 2018Publication date: January 31, 2019Inventors: Paul A. Lyons, Kenneth G.C. Smith, Eoin F. McKinney, Daniele Biasci, James Lee
-
Publication number: 20180010187Abstract: The present invention provides a method of assessing whether an individual is at high risk or low risk of inflammatory bowel disease (IBD) progression by determining the expression level of two or more genes in a whole blood sample. Also provided are methods for treating IBD in an individual who is determined to be at high risk or low risk for IBD progression, and kits for assessing whether an individual is at high risk or low risk for IBD progression. Arrays, and methods of providing arrays, of patient-identified selected gene expression products from a whole blood sample of a patient are also provided.Type: ApplicationFiled: July 5, 2017Publication date: January 11, 2018Inventors: Paul A. Lyons, Kenneth G.C. Smith, Eoin F. McKinney, Daniele Biasci, James Lee
-
Publication number: 20180010189Abstract: The present invention provides a method of assessing whether an individual is at high risk or low risk of inflammatory bowel disease (IBD) progression by determining the expression level of two or more genes in a whole blood sample. Also provided are methods for treating IBD in an individual who is determined to be at high risk or low risk for IBD progression, and kits for assessing whether an individual is at high risk or low risk for IBD progression. Arrays, and methods of providing arrays, of patient-identified selected gene expression products from a whole blood sample of a patient are also provided.Type: ApplicationFiled: July 17, 2017Publication date: January 11, 2018Inventors: Paul A. Lyons, Kenneth G.C. Smith, Eoin F. McKinney, Daniele Biasci, James Lee
-
Publication number: 20100293167Abstract: Methods and system for biological database indexing and query searching are described. In one embodiment, one or more words may be extracted from a biological sequence using a spacer. The spacer may be one or more characters within the biological sequence. The word and a position of the word within the biological sequence may be stored in a sequence index associated with the spacer. The sequence index may be capable of being used for an operation associated with the biological sequence.Type: ApplicationFiled: June 18, 2008Publication date: November 18, 2010Inventors: Daniele Biasci, Guido Giudetti, Massimiliano Andreazzoli